COYA Latest Press Releases

-- October 14, 2026 --

Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS Business Wire 8:00 AM

-- October 13, 2026 --

Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference Business Wire 8:00 AM

-- October 5, 2026 --

Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS Business Wire 8:00 AM

-- September 15, 2026 --

Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS Business Wire 8:00 AM

-- September 8, 2026 --

Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation Business Wire 8:00 AM

-- June 18, 2026 --

Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting Business Wire 8:00 AM

-- June 15, 2026 --

Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease Business Wire 8:00 AM

-- June 8, 2026 --

Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase Business Wire 8:00 AM

-- May 27, 2026 --

Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit Business Wire 8:00 AM

Market Data Delayed 15 Minutes